Histone acetylation modifiers in the pathogenesis of malignant disease.
about
Identification and characterization of the human ARD1-NATH protein acetyltransferase complexStem cells and ageing. The potential of stem cells to overcome age-related deteriorations of the body in regenerative medicine.The natural tumor suppressor protein maspin and potential application in non small cell lung cancerFinding the needle in the haystack: why high-throughput screening is good for your health.ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathwayInhibition of N-terminal lysines acetylation and transcription factor assembly by epirubicin induced deranged cell homeostasisComparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families.Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.Allyl isothiocyanate as a cancer chemopreventive phytochemical.Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotypeRomidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaMethod for generation of in vivo biotinylated recombinant antibodies by yeast mating.Mitochondrial DNA variants can mediate methylation status of inflammation, angiogenesis and signaling genes.Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cellsThe sirtuins in the pathogenesis of cancer.Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins.Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trialThe role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis.Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memorySuberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry.Analysis of class I and II histone deacetylase gene expression in human leukemia.Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways.In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaHistone deacetylase inhibition modulates cell fate decisions during myeloid differentiation.The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay.A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.Molecular testing in the diagnosis of differentiated thyroid carcinomas
P2860
Q24307878-D8247F53-FEE5-4DE8-B753-7C4AEB934641Q24539148-6750A28A-6A2B-41A4-9570-CFE127064518Q24604273-263934E4-2794-4BB4-A3C7-7D9A1E34841CQ24802613-9EA06287-D26D-4A1F-920C-5DC4BFF4ED20Q28272830-C43E5704-55A0-4B7D-B25C-2F1217CB97A5Q28484361-4252A640-389F-4464-A302-119759109978Q30886620-24A0FFCF-C43E-411D-BE26-470A6F9FD2E3Q33435113-3F9F7707-D4FA-4AFF-B9A3-BC0A72118A1CQ33622654-4651F16D-00FF-4C56-B404-376BEC8F46EEQ33860585-54B670E8-90CD-4835-A776-82C1A370C08DQ33862991-9FF5B2E9-D4D2-4B9F-8CFD-577693D1EFDCQ35182839-E807583F-A80C-4898-B3EB-DE01C1A2F6BAQ35186682-B4384099-3E53-4495-9D07-9749870837C1Q35613964-030FEC2C-92B6-4D61-8487-0BC8D3B884D7Q35882554-956898F9-608B-451B-9E2A-836669310751Q36001852-E9DA7077-EDF1-4B93-8956-45CEE90CFB43Q36001856-4F8C36F5-554F-433E-9293-9BF4481751D8Q36101923-626A276D-8637-4456-B476-EAB5DBD18915Q36610835-99E45EEE-7ABE-4254-B01A-D07F2BCCAA60Q36782553-E601E67C-03C1-4C3B-91C5-2088AB22C3ADQ37017072-221A1376-1496-4D68-8ED7-797E8A167EDCQ37201297-13CD8906-9D3B-4116-94B2-6BA2A307BA4AQ37332674-38A1D76F-9CF9-4CE7-B13C-0765AD4E0D6AQ37382318-4BF67001-2238-4BB9-8554-B92856EC27B0Q38588663-89EF542C-41FF-4BBC-8591-E28C7E2B620EQ39026671-C01B18CD-2A81-4F00-8254-3F26AEA621F2Q39177415-9E8FF14B-3624-4C89-AC85-ABEB5D7A4615Q39523561-B3718D9B-63BB-4545-AA1C-D18E8F4EA2C7Q39768627-62FF942C-CAE8-4BC6-AE9C-706A71697C9DQ42739964-F5588BE8-9281-4A6C-A235-8F77D1AD7B35Q49717083-3D787268-9016-4F5E-97FC-44A694087F16Q49804873-712B6FA8-DC9C-4B36-B06A-875269FA7A14Q58805430-AFA82EF2-58E9-4903-88D5-0A81B7DEAC3A
P2860
Histone acetylation modifiers in the pathogenesis of malignant disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Histone acetylation modifiers in the pathogenesis of malignant disease.
@ast
Histone acetylation modifiers in the pathogenesis of malignant disease.
@en
Histone acetylation modifiers in the pathogenesis of malignant disease.
@nl
type
label
Histone acetylation modifiers in the pathogenesis of malignant disease.
@ast
Histone acetylation modifiers in the pathogenesis of malignant disease.
@en
Histone acetylation modifiers in the pathogenesis of malignant disease.
@nl
prefLabel
Histone acetylation modifiers in the pathogenesis of malignant disease.
@ast
Histone acetylation modifiers in the pathogenesis of malignant disease.
@en
Histone acetylation modifiers in the pathogenesis of malignant disease.
@nl
P1433
P1476
Histone acetylation modifiers in the pathogenesis of malignant disease.
@en
P2093
Mahlknecht U
P304
P407
P577
2000-08-01T00:00:00Z